Why the study?
What are the safety and efficacy outcomes of various fibrinolytic therapies in patients with deep vein thrombosis?
Population
1498 patients with deep vein thrombosis (DVT)
Design
Cohort
Authors
Loading...
Age >50 linked to higher cerebral bleeding with DVT fibrinolysis; leaves open optimal regimen selection in prospective trials.
What are the safety and efficacy outcomes of various fibrinolytic therapies in patients with deep vein thrombosis?
Fibrinolytic therapy for DVT achieves revascularization but carries significant age-dependent risks of cerebral bleeding and site-dependent risks of pulmonary embolism.
Michael Martin (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: